Share-based Payment Arrangement, Expense of PMV Pharmaceuticals, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PMV Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • PMV Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,383,000, a 38% decline year-over-year.
  • PMV Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $5,830,000, a 45% decline year-over-year.
  • PMV Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,872,000, a 28% decline from 2023.
  • PMV Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $12,375,000, a 21% increase from 2022.
  • PMV Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,195,000, a 91% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PMV Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $5,830,000 $1,383,000 -$841,000 -38% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $6,671,000 $1,668,000 -$1,099,000 -40% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,770,000 $1,508,000 -$1,102,000 -42% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $8,872,000 $1,271,000 -$1,695,000 -57% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $10,567,000 $2,224,000 -$1,100,000 -33% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $11,667,000 $2,767,000 -$386,000 -12% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $12,053,000 $2,610,000 -$322,000 -11% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $12,375,000 $2,966,000 -$86,000 -2.8% 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $12,461,000 $3,324,000 +$876,000 +36% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $11,585,000 $3,153,000 +$635,000 +25% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $10,950,000 $2,932,000 +$755,000 +35% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,195,000 $3,052,000 +$1,285,000 +73% 01 Oct 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
Q3 2022 $8,910,000 $2,448,000 +$652,000 +36% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $8,258,000 $2,518,000 +$1,368,000 +119% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $6,890,000 $2,177,000 +$1,550,000 +247% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q3
Q4 2021 $5,340,000 $1,767,000 +$1,183,000 +203% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $4,157,000 $1,796,000 +$1,126,000 +168% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $3,031,000 $1,150,000 +$767,000 +200% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $2,264,000 $627,000 +$331,000 +112% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $1,933,000 $584,000 01 Oct 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
Q3 2020 $670,000 +$431,000 +180% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $383,000 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $296,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021 2021 Q1
Q3 2019 $239,000 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020 2020 Q3

PMV Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,872,000 -$3,503,000 -28% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $12,375,000 +$2,180,000 +21% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $10,195,000 +$4,855,000 +91% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $5,340,000 +$3,407,000 +176% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $1,933,000 +$1,025,000 +113% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2023 2022 FY
2019 $908,000 -$171,000 -16% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $1,079,000 01 Jan 2018 31 Dec 2018 10-K 03 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.